JNCI:乳腺癌风险评估工具BCRAT是否适用于≥75岁的老年女性

2016-01-15 Seven L 译 MedSci原创

乳腺癌的风险评估工具 (BCRAT, "Gail model")现已广泛用于乳腺癌预测,BCRAT危险因素包括:年龄、种族/民族、初潮年龄、分娩年龄、家庭史、既往乳腺活检良性和异型性。但是该工具并没有在≥75岁女性中验证。因此研究组就该问题进行了一项研究。该研究共纳入73072名来自NHS和97081名来自WHI的女性参与者。NHS参与者中非西班牙籍白人更多,占96.2%,WHI中该数字为84.7

乳腺癌的风险评估工具 (BCRAT, "Gail model")现已广泛用于乳腺癌预测,BCRAT危险因素包括:年龄、种族/民族、初潮年龄、分娩年龄、家庭史、既往乳腺活检良性和异型性。但是该工具并没有在≥75岁女性中验证。因此研究组就该问题进行了一项研究。

该研究共纳入73072名来自NHS和97081名来自WHI的女性参与者。NHS参与者中非西班牙籍白人更多,占96.2%,WHI中该数字为84.7%(P < .001),此外NHS中乳腺癌发生率比WHI低(1.8% vs 2.0%, P = .02)。乳腺癌发生率的预期/观察(E / O)比率在NHS组不同年龄段分别为:57-74岁 E/O=1.16 (95% CI= 1.09 to 1.23),≥75岁 E/O=1.31 (95% CI = 1.18 to 1.45,P = .02);WHI组该数值分别为:57-74岁 E/O=1.03 (95% CI = 0.97 to 1.09),≥75岁 E/O=1.10 (95% CI = 1.00 to 1.21,P = .21)。≥纳入的75岁女性是进行了钼靶检查且无重大疾病的女性,因此使得样本不具有广泛的代表性。无论年龄,两组队列中C值范围在0.56-0.58间。

研究结果表明,BCRAT乳腺癌预测模型能准确预测≥75岁进行了钼靶检查又无重大疾病的女性乳腺癌风险。研究者认为,考虑个人风险的非乳腺癌死亡的模型,可以提高老年女性乳腺癌风险的预测。

原始出处:

Schonberg MA, Li VW,et al.Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older.J Natl Cancer Inst. 2015 Nov 30;108(3).


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046740, encodeId=ef462046e40fe, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 19 03:17:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933700, encodeId=85ad1933e009e, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Nov 03 23:17:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770245, encodeId=1a281e70245a1, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu Jun 09 04:17:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061508, encodeId=5ad0206150883, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed May 25 00:17:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046740, encodeId=ef462046e40fe, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 19 03:17:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933700, encodeId=85ad1933e009e, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Nov 03 23:17:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770245, encodeId=1a281e70245a1, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu Jun 09 04:17:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061508, encodeId=5ad0206150883, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed May 25 00:17:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046740, encodeId=ef462046e40fe, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 19 03:17:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933700, encodeId=85ad1933e009e, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Nov 03 23:17:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770245, encodeId=1a281e70245a1, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu Jun 09 04:17:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061508, encodeId=5ad0206150883, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed May 25 00:17:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046740, encodeId=ef462046e40fe, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Tue Jan 19 03:17:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933700, encodeId=85ad1933e009e, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12585, encryptionId=71a81258504, topicName=NCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Nov 03 23:17:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770245, encodeId=1a281e70245a1, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Thu Jun 09 04:17:00 CST 2016, time=2016-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061508, encodeId=5ad0206150883, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed May 25 00:17:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
    2016-05-25 sjq027